Barouch, D. H., Tomaka, F. L., Wegmann, F., Stieh, D. J., Alter, G., Robb, M. L., Michael, N. L., Peter, L., Nkolola, J. P., Borducchi, E. N., Chandrashekar, A., Jetton, D., Stephenson, K. E., Li, W., Korber, B., Tomaras, G. D., Montefiori, D. C., Gray, G., Frahm, N., McElrath, M. J., Baden, L., Johnson, J., Hutter, J., Swann, E., Karita, E., Kibuuka, H., Mpendo, J., Garrett, N., Mngadi, K., Chinyenze, K., Priddy, F., Lazarus, E., Laher, F., Nitayapan, S., Pitisuttithum, P., Bart, S., Campbell, T., Feldman, R., Lucksinger, G., Borremans, C., Callewaert, K., Roten, R., Sadoff, J., Scheppler, L., Weijtens, M., Feddes-de Boer, K., van Manen, D., Vreugdenhil, J., Zahn, R., Lavreys, L., Nijs, S., Tolboom, J., Hendriks, J., Euler, Z., Pau, M. G., & Schuitemaker, H. (2018). evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet, 392(10143), 232–243. http://access.bl.uk/ark:/81055/vdc_100066537435.0x000054